ATE556069T1 - 1,2,4-triazin-3,5-dionverbindungen zur behandlung von erkrankungen, die auf die modulation des dopamin-d3-rezeptors ansprechen - Google Patents

1,2,4-triazin-3,5-dionverbindungen zur behandlung von erkrankungen, die auf die modulation des dopamin-d3-rezeptors ansprechen

Info

Publication number
ATE556069T1
ATE556069T1 AT08844723T AT08844723T ATE556069T1 AT E556069 T1 ATE556069 T1 AT E556069T1 AT 08844723 T AT08844723 T AT 08844723T AT 08844723 T AT08844723 T AT 08844723T AT E556069 T1 ATE556069 T1 AT E556069T1
Authority
AT
Austria
Prior art keywords
dopamine
triazine
receptor
modulation
treatment
Prior art date
Application number
AT08844723T
Other languages
English (en)
Inventor
Wilfried Braje
Sean Colm Turner
Andreas Haupt
Udo Lange
Herve Geneste
Karla Drescher
Liliane Unger
Ana Lucia Jongen-Relo
Anton Bespalov
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE556069(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE556069T1 publication Critical patent/ATE556069T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08844723T 2007-11-02 2008-10-31 1,2,4-triazin-3,5-dionverbindungen zur behandlung von erkrankungen, die auf die modulation des dopamin-d3-rezeptors ansprechen ATE556069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07119927 2007-11-02
PCT/EP2008/064795 WO2009056625A1 (en) 2007-11-02 2008-10-31 1,2,4,-triazin-3,5-dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor

Publications (1)

Publication Number Publication Date
ATE556069T1 true ATE556069T1 (de) 2012-05-15

Family

ID=40210491

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08844723T ATE556069T1 (de) 2007-11-02 2008-10-31 1,2,4-triazin-3,5-dionverbindungen zur behandlung von erkrankungen, die auf die modulation des dopamin-d3-rezeptors ansprechen

Country Status (29)

Country Link
US (1) US8492540B2 (de)
EP (1) EP2217593B1 (de)
JP (1) JP5559694B2 (de)
KR (1) KR20100094491A (de)
CN (1) CN101932574B (de)
AR (1) AR069150A1 (de)
AT (1) ATE556069T1 (de)
AU (1) AU2008320814B2 (de)
BR (1) BRPI0818726A2 (de)
CA (1) CA2704533C (de)
CL (1) CL2008003253A1 (de)
CO (1) CO6280473A2 (de)
CR (1) CR11410A (de)
DO (1) DOP2010000126A (de)
EC (1) ECSP10010227A (de)
ES (1) ES2386691T3 (de)
HK (1) HK1146628A1 (de)
IL (1) IL205468A0 (de)
MX (1) MX2010004830A (de)
MY (1) MY154066A (de)
NZ (1) NZ585051A (de)
PA (1) PA8802101A1 (de)
PE (1) PE20090950A1 (de)
RU (1) RU2478633C2 (de)
TW (1) TWI463984B (de)
UA (1) UA99634C2 (de)
UY (1) UY31448A1 (de)
WO (1) WO2009056625A1 (de)
ZA (1) ZA201003593B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505753B2 (en) 2012-08-08 2016-11-29 The Johns Hopkins University Inhibitors of D-amino acid oxidase
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
KR102643833B1 (ko) 2022-06-30 2024-03-06 현대제철 주식회사 이강종 연연주시 강종 예측 정합성 증대 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
FR2769913B1 (fr) * 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
TW200510395A (en) * 2003-06-05 2005-03-16 Abbott Gmbh & Co Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DE102004027359A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
JP4904267B2 (ja) * 2004-08-09 2012-03-28 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンd3受容体の調節に応答する障害の治療に好適な4−ピペラジニル−ピリミジン化合物
AU2005311452A1 (en) * 2004-12-02 2006-06-08 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine D3 receptor
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
KR20100051625A (ko) * 2007-06-28 2010-05-17 인터벳 인터내셔널 비.브이. Cb1 길항제로서의 치환된 피페라진

Also Published As

Publication number Publication date
PE20090950A1 (es) 2009-08-08
AR069150A1 (es) 2009-12-30
ES2386691T3 (es) 2012-08-27
DOP2010000126A (es) 2010-06-15
CL2008003253A1 (es) 2009-11-13
ECSP10010227A (es) 2010-08-31
UY31448A1 (es) 2009-05-29
AU2008320814A1 (en) 2009-05-07
JP2011502971A (ja) 2011-01-27
CN101932574A (zh) 2010-12-29
EP2217593A1 (de) 2010-08-18
ZA201003593B (en) 2011-02-23
WO2009056625A1 (en) 2009-05-07
IL205468A0 (en) 2010-12-30
CR11410A (es) 2010-09-13
MY154066A (en) 2015-04-30
CO6280473A2 (es) 2011-05-20
HK1146628A1 (en) 2011-06-24
PA8802101A1 (es) 2009-08-26
NZ585051A (en) 2012-03-30
CA2704533C (en) 2016-09-06
KR20100094491A (ko) 2010-08-26
CN101932574B (zh) 2014-07-23
CA2704533A1 (en) 2009-05-07
US8492540B2 (en) 2013-07-23
JP5559694B2 (ja) 2014-07-23
RU2478633C2 (ru) 2013-04-10
MX2010004830A (es) 2010-10-20
EP2217593B1 (de) 2012-05-02
US20100311755A1 (en) 2010-12-09
TWI463984B (zh) 2014-12-11
TW200927132A (en) 2009-07-01
RU2010122337A (ru) 2011-12-10
AU2008320814B2 (en) 2013-07-11
UA99634C2 (ru) 2012-09-10
BRPI0818726A2 (pt) 2015-04-22

Similar Documents

Publication Publication Date Title
ATE482939T1 (de) Neue antimikrobielle verbindungen, ihre synthese und ihre verwendung zur behandlung von säugetierinfektionen
ZA201006868B (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
NZ599513A (en) Compounds for the treatment of dyslipidemia and related diseases
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
EP2382176A4 (de) Verwendung von stickstoffhaltigen kurkuminanaloga zur behandlung von alzheimer-krankheit
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DK2303330T4 (da) Farmaceutiske sammensætninger til behandling af parkinsons sygdom
IN2012DN02679A (de)
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
ATE538114T1 (de) 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
DE602008000403D1 (de) Behandlung von medizinischen Implantaten, die kalkbeständig sind
ATE556069T1 (de) 1,2,4-triazin-3,5-dionverbindungen zur behandlung von erkrankungen, die auf die modulation des dopamin-d3-rezeptors ansprechen
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
ATE541831T1 (de) Verwendung von indolderivaten als nurr-1- aktivatoren zur behandlung von morbus parkinson
ATE524456T1 (de) Zur behandlung von erkrankungen, die auf eine modulation des serotonin-5-ht6-rezeptors ansprechen, geeignete chinolinverbindung
EP2349308A4 (de) Verbindungen zur behandlung von morbus alzheimer
DE602008002598D1 (en) Cyclohexylderivate
FR2938400B1 (fr) Equipement pour travaux agricoles au pied des vignes
ATE535517T1 (de) Benzolsulfonanilidverbindungen, die sich für die behandlung von erkrankungen eignen, die auf die modulation des serotonin-5-ht6-rezeptors ansprechen